FIELD: biotechnology.
SUBSTANCE: present invention relates to a bispecific antibody, and can be used in medicine.
EFFECT: disclosed antibody is capable of binding to receptors from superfamily TNF—CD137 and CD40, and can also be considered as a potential therapeutic agent for inducing activation of T-cells and used in treating or preventing oncological or viral diseases.
15 cl, 3 ex, 13 dwg, 9 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| TNF RECEPTOR-BINDING AGONISTS | 2016 |
|
RU2821343C2 |
| IL-12/P40 BINDING PROTEINS | 2006 |
|
RU2461571C2 |
| METHODS OF MODIFYING ANTIBODIES AND MODIFIED ANTIBODIES WITH IMPROVED FUNCTIONAL PROPERTIES | 2008 |
|
RU2540150C2 |
| ANTIBODY SPECIFICALLY BINDING TO ErbB3, AND USE THEREOF | 2016 |
|
RU2707121C2 |
| MICA/B ANTIBODIES BLOCKING MICA/B SHEDDING AND METHODS OF USE THEREOF | 2019 |
|
RU2815101C2 |
| CONSTRUCTED PAIRS OF HEAVY-LIGHT IMMUNOGLOBULIN CHAINS AND THEIR USE | 2013 |
|
RU2720472C2 |
| ANTI-PD-1 ANTIBODIES | 2015 |
|
RU2711141C2 |
| ISOLATED HUMAN CD45RC ANTIBODY, NUCLEIC ACID, EXPRESSION VECTOR, CELL, PHARMACEUTICAL COMPOSITION, USE THEREOF, IN VITRO METHOD OF DETECTING hCD45RC | 2019 |
|
RU2826421C2 |
| ANTIBODIES AGAINST SIGLEKA-15 FOR TREATING DISEASE ASSOCIATED WITH LOSS OF BONE MASS | 2010 |
|
RU2596392C2 |
| ANTIBODIES AND CHIMERIC ANTIGENIC RECEPTORS SPECIFIC TO CD19 | 2015 |
|
RU2741105C2 |
